Opinion|Videos|September 17, 2024
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Advertisement
Video content above is prompted by the following:
- What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
- What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
5